February 2026
M	T	W	T	F	S	S
	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28

Wolfgang Miesbach: Sophie Susen’s ”Long‑Term Prophylaxis in VWD” Talk at EAHAD 2026

Wolfgang Miesbach/LinkedIn; Sophie Susen/MHEMO

Feb 13, 2026, 11:17

Wolfgang Miesbach: Sophie Susen’s ”Long‑Term Prophylaxis in VWD” Talk at EAHAD 2026

Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn:

”Really appreciated Sophie Susen’s EAHAD 2026 talk on long‑term prophylaxis in severe von Willebrand disease.

‘Recombinant von Willebrand factor prophylaxis for severe von Willebrand disease: final results focusing on adults receiving once‑weekly prophylaxis in a phase 3b continuation study.’

Severe VWD often requires frequent VWF infusions; rVWF (vonicog alfa) is usually started at 40–60 IU/kg twice weekly, so safely reducing infusion frequency could meaningfully lower treatment burden for adults.

Data from the once‑weekly adult subgroup (n=5):
Over 35–36 months, treated spontaneous bleeding remained low (median sABR ≈1.0) with clear reductions versus historical baselines.
Once‑weekly rVWF at ~60 IU/kg per infusion maintained good bleed control for most, although 2 of 5 adults required escalation to twice‑weekly dosing after about 2 years because of breakthrough bleeds.

Safety was favourable and all 5 adults completed the study, but these promising findings must be interpreted with caution given the very small number of participants.”

Wolfgang Miesbach: Sophie Susen’s ''Long‑Term Prophylaxis in VWD'' Talk at EAHAD 2026